PUBLIC COMPANY
save$ALLOAllogene Therapeutics, Inc.
$ALLO2.0700-2.36%South San Francisco, CA, USupdated 35m ago
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
community read0 votes
pipeline
4
marketed
0
phase 3
0
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
2Phase 11Phase 21Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (2)
Active trials
- phase1A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- phase2Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- phase2Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
- phase2Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
- phase1Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
- phase1Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- —Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
- phase2Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 21, 26SELLYoshiyama Annie· SVP, Finance−$22K↗
- Mar 31, 26SELLBeneski Benjamin Machinas· SVP, Chief Technical Officer−$7K↗
- Mar 16, 26SELLChang David D· President and CEO−$118K↗
- Mar 16, 26SELLBeneski Benjamin Machinas· SVP, Chief Technical Officer−$12K↗
- Mar 2, 26SELLBeneski Benjamin Machinas· SVP, Chief Technical Officer−$19K↗
🐶 Hiring Signal
News
- Aura, Schrödinger trim workforcesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 1d ago
- FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer PatientsThe U.S. Food and Drug Administration today approved TREGZI, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease (GVHD)-free survival in adult pat…fda_press · 1mo ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that